# An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

> **NCT04764188** · — · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 800 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT04764188
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2027-05-10
- **Final completion:** 2027-05-10
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764188, "An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04764188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*